Headquartered in New York, NY Fiscal year ends December NASDAQ: PGNY progyny.com
Progyny provides women's health and family building benefits to employers, health plans and other benefit purchasers. Its programs cover fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being. The model combines clinical care through a Center of Excellence provider network, integrated pharmacy support through Progyny Rx, and personalized guidance from Progyny Care Advocates. Revenue is reported in two lines: fertility benefit services and pharmacy benefit services. As of September 30, 2026, Progyny served 607 fertility and family building clients with about 7.2 million average members. It expects more than 660 clients and about 8.3 million covered lives once its 2027 client cohort is live. Updated
A record selling season added 1.3 million covered lives, pointing to about 8.3 million covered lives in 2027. Management also raised the full-year revenue guidance midpoint to $1.365 to $1.385 billion.
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen…
Progyny provides women's health and family building benefits to employers, health plans and other benefit purchasers. Its programs cover fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being.
24/7 Wall St.'s 12-month price target for PGNY is $45.65, rated Buy. The Wall Street consensus target is $36.67. PGNY price prediction →
